Expert Consensus on Neoadjuvant Immunotherapy for NSCLC Expert Consensus on Neoadjuvant Immunotherapy for NSCLC
A new expert consensus provides guidance regarding the use of neoadjuvant immunotherapy in NSCLC.Translational Lung Cancer Research (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 22, 2021 Category: Surgery Tags: Hematology-Oncology Journal Article Source Type: news
Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
THURSDAY, April 1, 2021 -- Among patients with resected esophageal or gastroesophageal junction cancer who have received neoadjuvant chemoradiotherapy, disease-free survival is significantly longer with nivolumab adjuvant therapy versus placebo,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2021 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full details of the ...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full details of the ...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news
Studies Back Neoadjuvant Strategies for Melanoma Studies Back Neoadjuvant Strategies for Melanoma
Two analyses of neoadjuvant immunotherapy support more rigorous study with RCTs of neoadjuvant vs adjuvant strategies for melanoma, says Dr Weber.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 24, 2021 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news
Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS in the ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news
Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS in the ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news
Anthracycline-Free Neoadjuvant Regimen Safe, Effective for TNBC Anthracycline-Free Neoadjuvant Regimen Safe, Effective for TNBC
A taxane/platinum doublet works just as well as the standard-of-care anthracycline-containing regimen, plus it ' s cheaper and is less toxic.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Age Should Not Prevent Aggressive Esophageal Cancer Treatment Age Should Not Prevent Aggressive Esophageal Cancer Treatment
Neoadjuvant chemoradiation plus esophagectomy can be performed safely in well-selected older patients with locally advanced esophageal or esophagogastric junction cancer, according to a reviewMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Optimal Therapy for Esophageal Cancer Feasible in Fit Elderly
FRIDAY, Feb. 26, 2021 -- Patients 70 years and older with locally advanced esophageal or esophagogastric junction (EGJ) cancer should be considered for optimal, potentially curative therapy, including neoadjuvant chemoradiotherapy and surgical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 26, 2021 Category: Pharmaceuticals Source Type: news
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
(University of Texas M. D. Anderson Cancer Center) The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 18, 2021 Category: Cancer & Oncology Source Type: news
Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer
In the LCMC3 study, patients received 1200 mg of neoadjuvant atezolizumab IV every 3 weeks for two cycles followed by resection between 30 and 50 days from the first cycle.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
